JDD September 2023 Issue Highlights | Special Focus: Aesthetic Treatments
aesthetic treatmentsWith a special focus on aesthetic treatments, check out highlights from the September issue of the Journal of Drugs in Dermatology (JDD) straight from the Editor’s desk: A Randomized Control Trial Comparing the Efficacy of Platelet-Rich Plasma and 5% Topical Minoxidil for the Treatment of Androgenetic Alopecia suggests that PRP therapy demonstrates a higher efficacy compared to minoxidil for t …
aesthetic treatments
What’s New in Wound Healing
wound healingNext Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Hadar Lev-Tov, associate professor of clinical dermatology and cutaneous surgery at the University of Miami Miller School of Medicine. Watch as Dr. Lev-Tov shares some of the treatments that are emerging in wound healing. Find out why a beta blocker may be the most well-kept secret in he …
wound healing
Rituximab Therapeutic Cheat Sheet
RituximabRituximab was the first monoclonal antibody approved for cancer treatment and now in dermatology, this medication has been life-altering for patients with the severe, autoimmune blistering disease, pemphigus vulgaris. We continue our series, Therapeutic Cheat Sheet, with a closer look at rituximab, which is FDA-approved for the treatment of pemphigus vulgaris, and is also used off label for other …
Rituximab
Tapinarof Therapeutic Cheat Sheet
TAPINAROFTapinarof cream is a non-steroidal topical medication that was recently FDA approved in 2022 for the treatment of mild, moderate, or severe plaque psoriasis in adult patients. As biologic medications have continued to grow and become exceedingly present in the treatment of moderate to severe psoriasis, there has been very minimal, if any innovation in the space of topical treatments. Additionally, …
TAPINAROF
Azelaic Acid Therapeutic Cheat Sheet
azelaic acidAzelaic acid is a topical therapeutic agent which is FDA approved to treat papules and pustules of mild to moderate rosacea and mild to moderate acne vulgaris.  It was first approved by the FDA in 1995 and since its approval, has been used for many off-label conditions including disorders of hyperpigmentation. Its utility in various conditions can be attributed to its anti-microbial, anti-inflamm …
azelaic acid
error

Enjoy this blog? Please spread the word :)